Jaguar Health (JAGX) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind crossover clinical trial has entered the active treatment only single-blind extension to evaluate the longer term safety and efficacy of crofelemer powder for oral solution as adjunctive treatment to parenteral support to support regulatory submissions for the drug to treat this serious unmet medical need. The trial is being conducted at multiple centers with appropriate regulatory approvals in the United States, European Union, and United Arab Emirates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health Delays Quarterly Filing Briefly
- Jaguar Health granted extension to comply with Nasdaq bid price rule
- Jaguar Animal Health Granted Short Nasdaq Compliance Extension
- Jaguar Health’s Napo held preliminary discussion with FDA over crofelemer
- Jaguar Health Boosts Public Float to Regain Nasdaq Compliance